Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 10, 2018; 90 (15 Supplement) April 23, 2018

Meta-Analysis of Deflazacort vs Prednisone/Prednisolone in Patients with Duchenne Muscular Dystrophy (P2.325)

Basil Darras, Peter Riebling, Edward O’Mara, Gary Elfring, Xiaohui Luo, Panayiota Trifillis, Joseph McIntosh, Claudio Santos, Julie Parsons, Perry B. Shieh, Susan Apkon, Craig Campbell, Craig McDonald
First published April 9, 2018,
Basil Darras
1Children’s Hosp Boston Harvard Med School Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Riebling
2PTC Therapeutics, Inc South Plainfield NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edward O’Mara
2PTC Therapeutics, Inc South Plainfield NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary Elfring
2PTC Therapeutics, Inc South Plainfield NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaohui Luo
2PTC Therapeutics, Inc South Plainfield NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Panayiota Trifillis
2PTC Therapeutics, Inc South Plainfield NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph McIntosh
2PTC Therapeutics, Inc South Plainfield NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claudio Santos
2PTC Therapeutics, Inc South Plainfield NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie Parsons
3Children’s Hospital Colorado Aurora CO United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Perry B. Shieh
4UCLA Los Angeles CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Apkon
5Seattle Children’s Hospital Seattle WA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Craig Campbell
6Children’s Hospital London Health Sciences Centre London ON Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Craig McDonald
7UC Davis Dept. of PM&R Sacramento CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Meta-Analysis of Deflazacort vs Prednisone/Prednisolone in Patients with Duchenne Muscular Dystrophy (P2.325)
Basil Darras, Peter Riebling, Edward O’Mara, Gary Elfring, Xiaohui Luo, Panayiota Trifillis, Joseph McIntosh, Claudio Santos, Julie Parsons, Perry B. Shieh, Susan Apkon, Craig Campbell, Craig McDonald
Neurology Apr 2018, 90 (15 Supplement) P2.325;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To compare the efficacy of deflazacort vs prednisone/prednisolone in a posthoc meta-analysis of a phase 2b and phase 3 study.

Background: Corticosteroids can slow the loss of motor function in patients with Duchenne muscular dystrophy (DMD) and are considered part of the standard of care. The phase 2b (Study 007) and phase 3 (ACT DMD) clinical trials of ataluren are the largest, randomized, double-blind, placebo-controlled studies in nonsense mutation DMD to date.

Design/Methods: In a meta-analysis of the placebo arm of a phase 2b and phase 3 study, evidence comparing the efficacy of deflazacort vs prednisone/prednisolone was assessed post-hoc using the 6 minute walk test (6MWT) in patients with phenotypic and genotypic evidence of DMD aged ≥ 7 y, a baseline 6-minute walk distance (6MWD) ≥ 150 m, and ≤80% of predicted for their age and height. Patients in the placebo arms of each study received deflazacort (n=64) or prednisone/prednisolone (n=82) for 48 weeks after being on that same treatment for ≥12 months prior to the study start. The primary endpoint was change from baseline to week 48 in 6MWD. Safety parameters were also assessed.

Results: The weighted estimate of the treatment differences in 6 MWD (m, ±SEM) is 34.1m ± 13.5m and 95% CI of 7.6 to 60.7, showing a significant difference (p=0.006) favoring deflazacort. Respective adverse events ≥10% for deflazacort or prednisone/prednisolone were: vomiting (21.9%, 19.5%) headache (18.8%, 20.7%), nasopharyngitis (12.5%, 24.4%), fall (14.1%, 18,3%) diarrhea (12.5%, 14.6%), upper abdominal pain (7.8%, 17.1%), cough (9.4%, 15.9%), pain in extremity (12.5%, 11.0%), pyrexia (9.4%, 12.2%).

Conclusions: Deflazacort appeared to be more effective than prednisone/prednisolone in delaying progression of DMD.

Study Supported by: PTC Therapeutics, Inc

Disclosure: Dr. Riebling has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with PTC Therapeutics. Dr. O'Mara has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with PTC Therapeutics, Inc. Dr. Elfring has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with PTC Therapeutics, Inc. Dr. Luo has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with PTC Therapeutics, Inc. Dr. Trifillis has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with PTC Therapeutics, Inc. Dr. McIntosh has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with PTC Therapeutics. Dr. McIntosh holds stock and/or stock options in PTC Therapeutics. Dr. Santos has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with PTC Therapeutics, Inc. Dr. Parsons has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, AveXis, Sarepta. Dr. Parsons has received research support from Biogen, AveXis, PTC, Sarepta. Dr. Shieh has nothing to disclose. Dr. Apkon has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen. Dr. Apkon has received research support from PTC, Sarepta, and Eli Lilly and Marathon Pharm. Dr. Campbell has nothing to disclose. Dr. McDonald has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with PTC, Santhera, Sarepta, Catabasis, Mitobridge, Cardero, Capricor. Dr. McDonald has received research support from PTC, Sarepta, Santhera, Pfizer, Marathon.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (16)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise